



**FOCUS**

THE TARGETED **LDL** GOALS

# Bemzire-R 40

Bempedoic acid 180 mg + Rosuvastatin 40 mg Tablets

## Reach the LDL Goals

In Clinical ASCVD



High Risk ASCVD



In Primary prevention where LDL > 190 mg/dl or  
In Diabetes Mellitus

# Bemzire-R 40

Bempedoic acid 180 mg + Rosuvastatin 40 mg Tablets

## DESCRIPTION:

Bemzire-R 40 is available as film coated tablet of Bempedoic acid 180mg and Rosuvastatin 40mg. This combination medication is used along with a proper diet and other medications to help lower "bad" cholesterol (such as LDL) in the blood.

## INDICATION:

As adjunct to diet and maximally tolerated statin therapy for patients with ASCVD and/or heterozygous familial hypercholesterolemia who require additional LDL-C lowering.

## MECHANISM OF ACTION:

### Bempedoic Acid:

Bempedoic acid is a once-daily, oral, first-in-class - adenosine triphosphate-citrate lyase (ACL) inhibitor.

- ✓ Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearance.

### Rosuvastatin:

Rosuvastatin is in a class of medications called HMG-CoA reductase inhibitors (statins).

- ✓ It works by slowing the production of cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body.

## DOSAGE AND ADMINISTRATION:

- The recommended dosage of Bempedoic acid with maximally tolerated statin therapy is 180mg one tablet orally once a day.
- The recommended dosage of Rosuvastatin is 40 mg once a day (reserved for those who have not achieved their LDL-C goal with a 20 mg dose).

## PRESENTATION:

Bemzire-R 40 is available as 10 tablets in a strip.

### References:

1) [9] Ballantyne CM, Banach M, Mancini GB, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. *Atherosclerosis* 2018;277:195-203.

2) Nexlizet (bempedoic acid and ezetimibe) prescribing information. Ann Arbor, MI: Esperion Therapeutics; 2020.

3) Bilen O, Ballantyne CM: Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. *Curr Atheroscler Rep*. 2016 Oct;18(10):61. doi: 10.1007/s11883-016-0611-4. [Article]

4) <https://reference.medscape.com/drug/nexlizet-bempedoic-acid-ezetimibe-1000355>

## La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,  
S.G. Highway, Ahmedabad-380015, Gujarat, India.  
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998  
E-mail: info@larenon.com | Web: www.larenon.com

I am: \_\_\_\_\_  
Call me on: \_\_\_\_\_  
Mail me at: \_\_\_\_\_

©2022 All rights reserved, La Renon Healthcare Private Limited